Centro Oncológico y Tratamiento Oncología - CDIEM

María Luisa Santander 485, 7500859 Providencia, Región Metropolitana, Chile

Select an option

I am a doctor

I am a sponsor

Our team

Medical staff

Ricardo Silva

Open studies

Lung cancer

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC - MB12-C-01-22 - Laboratorio Elea Phoenix S.A.

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer - MARYGOLD - Amgen

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) - Eucalyptus - Amgen

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

Head and neck cancer

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients - MCLA-158-CL02 - Merus N.V.

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) - MCLA-158-CL03 - Merus N.V.

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

Bile Duct Cancer

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer - JZP598-302 - HERIZON-BTC-302 - Jazz Pharmaceuticals

Kidney cancer

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

Liver Cancer

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

Prostate cancer

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

Solid tumors

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

Urothelial cancer

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

About usOur mission Our team Partners FAQs

Medical newsLatest news Studies Interviews Testimonials

ProductsUEPM Onco UEPM Physicians

LinksDownloads

Centro Oncológico y Tratamiento Oncología - CDIEM

María Luisa Santander 485, 7500859 Providencia, Región Metropolitana, Chile

Select an option

I am a doctor

I am a sponsor

Our team

Medical staff

Ricardo Silva

Open studies

Lung cancer

Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC - MB12-C-01-22 - Laboratorio Elea Phoenix S.A.

A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer - MARYGOLD - Amgen

Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab) - Eucalyptus - Amgen

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

Head and neck cancer

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients - MCLA-158-CL02 - Merus N.V.

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) - MCLA-158-CL03 - Merus N.V.

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

Bile Duct Cancer

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer - JZP598-302 - HERIZON-BTC-302 - Jazz Pharmaceuticals

Kidney cancer

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

Liver Cancer

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

Prostate cancer

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

Solid tumors

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

Urothelial cancer

Study of XL092 in Combination With Immuno-Oncology Agents in Subjects With Solid Tumors - STELLAR-002 - Exelixis

About usOur mission Our team Partners FAQs

Medical newsLatest news Studies Interviews Testimonials

ProductsUEPM Onco UEPM Physicians

LinksDownloads